InsiderSignal.AI

InsiderSignal.ai

AGIO - Agios Pharmaceuticals, Inc.

Insider Sale by Goff Brian (CEO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

1 week ago, Goff Brian, serving as CEO at Agios Pharmaceuticals, Inc. (AGIO), sold 19,068 shares at $34.71 per share, for a total transaction value of $661,850.00. Following this transaction, Goff Brian now holds 184,508 shares of AGIO.

This sale represents a 9.00% decrease in Goff Brian's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Thursday, April 2, 2026 and publicly disclosed via SEC Form 4 filing on Monday, April 6, 2026, 4 days after the trade was made.

Agios Pharmaceuticals, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Goff Brian

Goff Brian

CEO

Brian Goff is the Chief Executive Officer and a member of the board of directors at Agios Pharmaceuticals, Inc. (AGIO), a position he has held since August 2022.[[1]](https://globalgenes.org/raredaily/agios-names-brian-goff-as-ceo/)[[2]](https://www.agios.com/about-us/leadership/brian-goff/)[[6]](https://www.agios.com/about-us/leadership/) With over 30 years of experience in the biopharmaceutical industry, particularly in rare diseases, Goff has led global commercial operations, sales, and marketing efforts at major companies.[[2]](https://www.agios.com/about-us/leadership/brian-goff/)[[5]](https://fintool.com/app/research/companies/NTLA/people/brian-goff) Prior to Agios, Goff served as Executive Vice President and Chief Commercial and Global Operations Officer at Alexion Pharmaceuticals until its acquisition by AstraZeneca in 2021, where he oversaw worldwide commercial teams, manufacturing, and supply.[[1]](https://globalgenes.org/raredaily/agios-names-brian-goff-as-ceo/)[[2]](https://www.agios.com/about-us/leadership/brian-goff/)[[4]](https://www.biopharmadive.com/news/agios-new-ceo-fouse-goff-rare-disease/627107/)[[5]](https://fintool.com/app/research/companies/NTLA/people/brian-goff) His previous roles include Chief Operating Officer and board member at Neurovance (acquired by Otsuka in 2017), Executive Vice President and President of the Hematology Division at Baxalta (acquired by Shire in 2016), and Global Hemophilia Franchise Head at Baxter Healthcare.[[1]](https://globalgenes.org/raredaily/agios-names-brian-goff-as-ceo/)[[2]](https://www.agios.com/about-us/leadership/brian-goff/)[[5]](https://fintool.com/app/research/companies/NTLA/people/brian-goff) Earlier, he held increasing responsibilities in sales and marketing at Novartis Pharmaceuticals and Johnson & Johnson's pharmaceutical division.[[2]](https://www.agios.com/about-us/leadership/brian-goff/) Goff holds an MBA from the Wharton School at the University of Pennsylvania and a Bachelor of Arts (Phi Beta Kappa) from Skidmore College.[[1]](https://globalgenes.org/raredaily/agios-names-brian-goff-as-ceo/)[[2]](https://www.agios.com/about-us/leadership/brian-goff/)[[5]](https://fintool.com/app/research/companies/NTLA/people/brian-goff) He also serves on the board of Intellia Therapeutics since June 2024 and has been recognized as 'Mentor of the Year' by the Healthcare Businesswomen’s Association in 2014.[[2]](https://www.agios.com/about-us/leadership/brian-goff/)[[5]](https://fintool.com/app/research/companies/NTLA/people/brian-goff)

View full insider profile →

Trade Price

$34.71

Quantity

19,068

Total Value

$661,850.00

Shares Owned

184,508

Trade Date

Thursday, April 2, 2026

7 days ago

SEC Filing Date

Monday, April 6, 2026

Filed 4 days after trade

HEALTHCAREBIOTECHNOLOGY

About Agios Pharmaceuticals, Inc.

Company Overview

No company information available
View news mentioning AGIO

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5419957

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime